Shire surprises by tapping new CEO

Surprise! You're the next CEO. So said Shire to CFO Angus Russell (photo), who got an unexpected promotion to the company's top slot. The board moved present CEO Matt Emmens to non-executive chair, replacing James Cavanaugh, who retires in June. The changes won't take place until Cavanaugh's exit.

So who is Angus Russell? The 51-year old has been CFO at Shire since 1999, helping to usher the company through several mergers. Before that, he worked in finance, strategy, and marketing at several pharma companies, including AstraZeneca.

- check out Shire's statement
- read the report from MarketWatch

Related Articles:
New guard takes over Big Pharma. Report
Shire on lookout for acquisitions. Report
Shire to Massachusetts: Pass incentive bill now. Report
FDA approves Shire's new ulcerative colitis drug. Report

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.